Table 1. Clinicopathological patient characteristics.

Variable		Value [mean ± SD (range)]
Age (yrs)		64 ± 15 (26 - 93)
Variable		Value [median (95% CI)]
Follow-up time (ms)		46.7 (31.1 - 55.8)
Variable		Value [n (%)]
Tumor stage	pT1a	16 (16)
	pT1b	67 (65)
	pT2	15 (14)
	pT3	1 (1)
	ND	4 (4)
Depth of stromal invasion	≤ 1mm	12 (12)
	> 1mm	75 (73)
	ND	16 (15)
Lymph node involvement	Present	31 (30)
	Absent	40 (39)
	ND	32 (31)
Metastasis	Present	5 (5)
	Absent	94 (91)
	ND	4 (4)
Tumor grade	1	12 (12)
	2	66 (64)
	3	24 (23)
	ND	1 (1)
Lymphovascular space invasion	Present	8 (8)
	Absent	80 (78)
	ND	15 (14)
Haemangioinvasion	Present	6 (6)
	Absent	82 (80)
	ND	15 (14)
Local surgical treatment	Wide local excision	15 (15)
	Partial vulvectomy	35 (34)
	Vulvectomy	49 (47)*
	Punch biopsy only	4 (4)**
Tumor-free margins	Present	86 (84)
	Absent	17 (16)
Lymph node dissection	Sentinel	4 (4)
	Inguinal (uni-, bilateral)	66 (64)***
	No lymph node dissection	33 (32)
Radiation therapy	Vulvar	12 (12)
	Inguinal	8 (8)
	Vulvar & inguinal	22 (21)****
	No radiation	61 (59)
Chemotherapy	Chemotherapy	1 (1)
	Concurrent chemoradiation	3 (3)
	No chemotherapy	99 (96)
Disease status	No evidence of disease	64 (62)
	Recurrent disease	36 (35)
	Lost to follow-up	3 (3)
Outcome	Alive	61 (59)
	Tumor-related death	33 (32)
	Non tumor-related death	8 (8)
	Lost to follow-up	1 (1)

CI, confidence interval; ms, months; ND, not determined; SD, standard deviation; yrs, years.

^*, includes 9 cases of concurent pelvic exenteration.

^**, surgery was not performed due to death before surgery (2) or inoperable morbidity (2).

^***, in 4 cases concurrent pelvic/paraaortic lymphadenectomy was performed.

^****, in 12 cases concurrent pelvic/iliac radiation therapy was performed.